A multi-faceted stool-based assay that covered three methylated biomarkers (SEPT9, NDRG4, BMP3), three mutated genes (KRAS, BRAF, PI3KCA), FIT and a bacteria level measurement of Fusobacterium nucleatum and Parvimonas micra, generated an increase in CRC detection rates from stage I to stage III, followed by a decrease in stage IV [62]. This evidence concerns the gene KRAS and colorectal carcinoma.